New advances in vaccine delivery systems.
Successful application of the next generation of vaccines will require that protection be induced with a minimal number of administrations, and that a practical approach to inducing immunity at mucosal surfaces be developed. For these reasons, vaccine-containing microspheres were formulated from the biodegradable and biocompatible copolymer poly(DL-lactide-co-glycolide) [DL-PLG]. Subcutaneous immunization of mice with 1- to 10-microns microspheres containing a toxoid vaccine of staphylococcal enterotoxin B (SEB) induced a 500-fold potentiation of the circulating antitoxin response. Strong adjuvant activity was dependent on the microspheres being no more than 10 microns in diameter and required that the antigen was within the particles. The rate of DL-PLG biodegradation is a function of the ratio of lactide to glycolide, and the co-injection of SEB toxoid microspheres formulated with two different DL-PLG ratios stimulated both a primary and an anamnestic secondary antitoxin response. When it was administered by the oral or intratracheal (IT) route, microencapsulated SEB toxoid was found to be effective in the induction of concurrent circulating and disseminated mucosal antibody responses. Female rhesus macaques immunized with a microencapsulated simian immunodeficiency virus (SIV) vaccine produced high levels of circulating anti-SIV antibodies, and following oral or IT boosting, specific antibodies were found in vaginal wash fluids. Vaginal challenge with viable homologous SIV resulted in the infection of three out of four nonimmunized but only one out of seven microsphere-immunized macaques. Thus, DL-PLG microspheres are a promising approach to the delivery of vaccines, combining adjuvant activity with controlled release and effective presentation to mucosally associated lymphoid tissues (MALT).
Eldridge
J H
JH
Department of Medicine, University of Alabama at Birmingham.
Staas
J K
JK
Chen
D
D
Marx
P A
PA
Tice
T R
TR
Gilley
R M
RM
D000276:Adjuvants, Immunologic; D000818:Animals; D001673:Biodegradation, Environmental; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D005260:Female; D008253:Macaca mulatta; D008863:Microspheres; D009092:Mucous Membrane / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D014612:Vaccines